CXCR4 and diffuse large B-cell lymphoma: Unlike BCWM.1 cells, mAbo treatment led to less effective migration enhancement in DHL6 cells (Figure 2A and Figure S3E), corroborating with the restricted CXCR4 responsiveness observed in DLBCL cells [28].